Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-05-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-1488PMID 27179111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

  2015cited by this paper
• Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

  2015cited by this paper
• Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.

  2015cited by this paper
• ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

  2014influential reference
• Response Prediction to Neoadjuvant Chemotherapy: Comparison between Pre-Therapeutic Gene Expression Profiles and In Vitro Chemosensitivity Assay

  2013cited by this paper
• TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

  2013cited by this paper
• Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer

  2013cited by this paper
• A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer

  2013cited by this paper
• Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer

  2013influential reference
• Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy.

  2013cited by this paper
• Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model

  2013cited by this paper
• Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis

  2013cited by this paper
• Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy

  2013influential reference
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer

  2012cited by this paper
• Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model

  2012cited by this paper
• Slug and Sox9 cooperatively determine the mammary stem cell state.

  2012cited by this paper
• Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

  2012cited by this paper
• Abstract PD10-06: CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors

  2012cited by this paper
• Aldehyde dehydrogenase 1‐positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node‐positive breast cancer

  2012cited by this paper
• Functional Significance of Aurora Kinase A Regulatory Interactions with p53–ERα Complex in Human Breast Cancer Cells

  2011cited by this paper
• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

  2011cited by this paper
• HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

  2011cited by this paper
• Multifactorial approach to predicting resistance to anthracyclines.

  2011cited by this paper
• Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer.

  2010cited by this paper
• Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment

  2010cited by this paper
• Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

  2010cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

  2010cited by this paper
• ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

  2009cited by this paper
• Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

  2009cited by this paper
• A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

  2009cited by this paper
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

  2009cited by this paper
• Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

  2009cited by this paper
• Tumor microenvironment: Modulation by decorin and related molecules harboring leucine‐rich tandem motifs

  2008cited by this paper
• A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer

  2008cited by this paper
• An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer

  2008cited by this paper
• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  2008cited by this paper
• Prognostic value of Bcl‐2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy

  2008cited by this paper
• uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

  2008cited by this paper
• Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

  2007cited by this paper
• ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

  2007cited by this paper
• Proliferation marker Ki-67 in early breast cancer.

  2005cited by this paper
• Expression of the Transcription Factors Snail, Slug, and Twist and Their Clinical Significance in Human Breast Cancer

  2005cited by this paper
• Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer.

  2003cited by this paper
• Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

  2002cited by this paper
• Retinoid, Retinoic Acid Receptor β and Breast Cancer

  2002cited by this paper
• Retinoid, retinoic acid receptor beta and breast cancer.

  2002cited by this paper
• Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2

  2001cited by this paper
• Expression level of Bcl-2 determines anti- or proapoptotic function.

  1999cited by this paper
• The anti‐apoptosis function of Bcl‐2 can be genetically separated from its inhibitory effect on cell cycle entry

  1997cited by this paper

• NMB promotes the progression of colorectal cancer by regulating the NF-κB/P65 signaling pathway

  2025cites this paper
• TGFB2 Gene Methylation in Tumors with Low CD8+ T-Cell Infiltration Drives Positive Prognostic Overall Survival Responses in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Expression and biological significance of topoisomerase II α (TOP2A) in oral squamous cell carcinoma

  2024cites this paper
• Lipid profiling of RON and DEK-dependent signaling in breast cancer guides discovery of gene networks predictive of poor outcomes

  2024cites this paper
• On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer

  2024cites this paper
• Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer

  2023cites this paper
• Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention

  2023cites this paper
• Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

  2023cites this paper
• DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival

  2022cites this paper
• COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

  2022cites this paper
• Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer

  2022cites this paper
• CHSY3 As A Potential Therapeutic Target For Gastric Cancer

  2022cites this paper
• NMB as a Novel Prognostic Biomarker in Colorectal Cancer Correlating with Immune Infiltrates

  2022cites this paper
• Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma

  2021cites this paper
• FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population

  2021cites this paper
• Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

  2021cites this paper
• Immune Microenvironment-Related Genes Contribute to Clinical Prognosis in Patients with Triple-Negative Breast Cancer

  2021cites this paper
• Consensus molecular subtypes of primary colon tumors and their hepatic metastases

  2021cites this paper
• Integrated analysis and identification of nine-gene signature associated to oral squamous cell carcinoma pathogenesis

  2021cites this paper
• Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer

  2021cites this paper
• Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer

  2021cites this paper
• Early Prediction of Tumor Response to Neoadjuvant Chemotherapy and Clinical Outcome in Breast Cancer Using a Novel FDG-PET Parameter for Cancer Stem Cell Metabolism

  2020cites this paper
• A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer

  2020cites this paper
• Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients

  2020cites this paper
• Transcriptome analysis reveals key signature genes involved in the oncogenesis of lung cancer

  2020cites this paper
• Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

  2020influential citation
• ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

  2020cites this paper
• Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques

  2020cites this paper
• TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing

  2020cites this paper
• Identification of a prognostic 28-gene expression signature for gastric cancer with lymphatic metastasis

  2019cites this paper
• Identification of differentially expressed protein-coding genes in lung adenocarcinomas.

  2019cites this paper
• Screening of core genes and pathways in breast cancer development via comprehensive analysis of multi gene expression datasets

  2019cites this paper
• Optimització del tractament oncològic pel pacient amb càncer colorectal metastàtic RAS natiu

  2019cites this paper
• Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis

  2019cites this paper
• Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives

  2019cites this paper
• Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.

  2019cites this paper
• Identification of core genes and potential molecular mechanisms in breast cancer using bioinformatics analysis.

  2019cites this paper
• Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and after Neoadjuvant Chemotherapy in Breast Cancer

  2019influential citation
• External Validation of Consensus Molecular Subtyping of Colorectal Adenocarcinoma

  2019cites this paper
• TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway.

  2018cites this paper
• Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer

  2018cites this paper
• Anti-tumor responses to hypofractionated radiation in mice grafted with triple negative breast cancer is associated with decorin induction in peritumoral muscles

  2018cites this paper
• High levels of serum CA15‐3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non‐pathological complete response after neoadjuvant chemotherapy

  2018cites this paper
• Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A

  2018cites this paper
• Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

  2018cites this paper
• Neoadjuvant chemotherapy affects molecular classification of colorectal tumors

  2017cites this paper
• Evaluating Common Strategies for the Efficiency of Feature Selection in the Context of Microarray Analysis

  2017cites this paper
• Evaluation of the prognosis as well as tumor marker levels and immune function of Fuzheng Xiaoliu decoction combined with paclitaxel treatment of advanced breast cancer

  2016cites this paper
• Chemoresistance and targeted therapies in ovarian and endometrial cancers

  2016influential citation
• Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes

  2016cites this paper